Nivolumab

Drug Profile

Nivolumab

Alternative Names: Anti-PD-1 monoclonal antibody - Medarex/Ono; BMS-936558; MDX-1106; Nivolumab BMS; ono-0123; ONO-4538; Opdivo

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Medarex; Ono Pharmaceutical
  • Developer AIO Studien gGmbH; Bavarian Nordic; Bristol-Myers Squibb; Duke University Medical Center; Eli Lilly; Grupo Espanol Multidisciplinar de Melanoma; Incyte Corporation; Janssen Research & Development; Kyowa Hakko Kirin; Medarex; National Cancer Center (Tokyo); National Cancer Centre (Singapore); National Cancer Institute (USA); Nektar Therapeutics; Neon Therapeutics; Netherlands Cancer Institute; Ono Pharmaceutical; Pharmacyclics; Seattle Genetics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Registered Head and neck cancer; Hodgkin's disease; Urogenital cancer
  • Preregistration Colorectal cancer; Gastric cancer
  • Phase III Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Multiple myeloma; Oesophageal cancer; Ovarian cancer; Small cell lung cancer
  • Phase II Acute myeloid leukaemia; Breast cancer; Cancer; Carcinomatous meningitis; Cervical cancer; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Prostate cancer; Soft tissue sarcoma; Testicular cancer; Uterine cancer; Uveal melanoma
  • Phase I/II Bladder cancer; Haematological malignancies; Non-Hodgkin's lymphoma; Peritoneal cancer; Rectal cancer; Solid tumours
  • Phase I Biliary cancer; Chronic myeloid leukaemia; Glioma; Hepatitis C

Most Recent Events

  • 27 Apr 2017 Bristol-Myers Squibb initiates an expanded access for Cancer (In children, In adolescents) before April 2017 (NCT03126643)
  • 21 Apr 2017 CHMP recommends approval of nivolumab for Urogenital Carcinoma (Late-stage disease, Inoperable/Unresectable, Recurrent, Second-line therapy or greater) in European Union
  • 20 Apr 2017 Bristol-Myers Squibb and ONO Pharmaceutical plan a phase III trial for Non squamous non small cell lung cancer (Combination therapy, Treatment-naive, Late-stage disease) in Japan, South Korea and Taiwan (JapicCTI173560)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top